
Clinical efficacy and safety of folic acid and vitamin B₁₂ for the adjuvant treatment of schizophrenia: a systematic review and meta-analysis.

Kai Niu¹, Ximin Zhao¹, Ying Wei² and Yuefeng Wang¹

¹Department of Psychiatry, Zhoushan Second People's Hospital, Zhoushan, Zhejiang Province, China.

²Medical Record Statistics Office, Zhoushan Second People's Hospital, Zhoushan, Zhejiang Province, China.

Key words: folic acid; meta-analysis; schizophrenia; vitamin B₁₂.

Abstract. Given the different effects of folate and vitamin B₁₂ on the adjuvant treatment of schizophrenia (SCH), their efficacy and safety as adjuvant therapies for SCH were systematically evaluated by evidence-based medicine. Publication retrieval was performed using authoritative databases such as the Cochrane Library, PubMed, and Web of Science to screen randomized controlled trials (RCTs). After the quality evaluation and data extraction of included studies, eligible RCTs were systematically reviewed using Review Manager 5.2 software. In total, 14 RCTs were included. The results of the meta-analysis revealed that as the adjuvant therapy for SCH, vitamin B₁₂ differed significantly from folate in terms of anxiety relief rate [odds ratio (OR)=1.28, 95% confidence interval (CI) (1.02, 1.61), p=0.03, I²=0%, Z=2.13]. However, there were no significant differences in the incidence rate of mania [OR=1.13, 95% CI (0.78,1.65), p=0.65, I²=36%, Z=0.65], total efficacy [OR=1.06, 95% CI (0.72, 1.56), p=0.77, I²=0%, Z=0.30] and incidence rate of adverse reactions [OR=1.15, 95% CI (0.88, 1.49), p=0.31, I²=0%, Z=1.03]. Although folate and vitamin B₁₂ exhibit no significant differences in the adjuvant treatment of SCH, vitamin B₁₂ exerts markedly fewer side effects than folate drugs, and it is of determinant significance for the clinical adjuvant medication of SCH.

Eficacia clínica y seguridad del ácido fólico y la vitamina B₁₂ como tratamiento adyuvante de la esquizofrenia: una revisión sistemática y metanálisis.

Invest Clin 2023; 64 (3): 424 – 436

Palabras clave: ácido fólico; metanálisis; esquizofrenia; vitamina B₁₂.

Resumen. En vista de los diferentes efectos del folato y la vitamina B₁₂ en el tratamiento adyuvante de la esquizofrenia (SCH), su eficacia y seguridad como terapia adyuvante para SCH fueron evaluadas sistemáticamente mediante la medicina basada en la evidencia. La recuperación de publicaciones se realizó en base a bases de datos autorizadas como Cochrane Library, PubMed y Web of Science para la selección de ensayos controlados aleatorios (ECA). Después de la evaluación de la calidad y la extracción de datos de los estudios incluidos, los ECA elegibles se revisaron sistemáticamente mediante el software Review Manager 5.2. En total, se incluyeron 14 ECA. Los resultados del metanálisis revelaron que, como terapia adyuvante para la SCH, la vitamina B₁₂ difería significativamente del folato en términos de tasa de alivio de la ansiedad [odds ratio (OR) = 1,28, intervalo de confianza (IC) del 95% (1,02, 1,61), p=0,03, I²=0%, Z=2,13], pero no hubo diferencias significativas en la tasa de incidencia de manía [OR=1,13, IC 95% (0,78,1,65), p=0,65, I²=36%, Z= 0,65], eficacia total [OR=1,06, IC 95% (0,72, 1,56), p=0,77, I²=0%, Z=0,30] y tasa de incidencia de reacciones adversas [OR=1,15, IC 95% (0,88, 1,49), p=0,31, I²=0%, Z=1,03]. Aunque el folato y la vitamina B₁₂ no presentan diferencias significativas en el tratamiento adyuvante de la SCH, la vitamina B₁₂ ejerce notablemente menos efectos secundarios que los fármacos de folato y tiene una importancia orientativa para la medicación adyuvante clínica de la SCH.

Received: 16-11-2022

Accepted: 15-04-2023

INTRODUCTION

Schizophrenia (SCH) is a chronic mental disorder that involves social, cognitive, and emotional problems and has a lifetime prevalence of 1% in the population. As a chronic disease, SCH is usually accompanied by physical illness, malnutrition, and reduced self-care practices, all of which can cause vitamin deficiency¹. Nutritional deficiencies often coexist with SCH, which is attributed to the patients' tendency to have higher calorie diets with saturated fat in-

stead of fiber foods such as fruits and vegetables. Previous studies have revealed deficiencies of nutrients, such as folate and vitamin B₁₂ in SCH patients resulting from less time on outdoor activities^{2,3}. Vitamin B₁₂ and folate levels decline in patients with SCH⁴. Alcoholism and drug addictions are viewed as chronic diseases featured by recurrence, in common with SCH. However, the prevalence data of illicit drug addiction worldwide are still lacking. Like SCH, alcoholism, and drug addictions may cause adverse effects on cognitive function and

induce malnutrition⁵. In addition, excessive drinking is a common phenomenon in developed countries, which affects nutrient intake and metabolism, leading to malnutrition, and also causes damage to multiple organs. Although folate and vitamin B₁₂ deficiencies are frequently present in chronic alcohol drinkers, the impact of long-term drinking on vitamin B₁₂ and folate levels has not yet reached a consensus. Thus, the data about correlations of vitamin D and other vitamin deficiencies with the risk of alcoholism are also insufficient to support the final conclusion⁶. Recently, vitamin B₁₂ has been demonstrated to be vital for hemostasis and multiple physiological functions, as well as the pathogenesis of diseases such as cancer, autoimmune disorder, senile dementia, cognitive impairment, and SCH⁷. It was also reported in another study that vitamin B₁₂ acts as an essential player in SCH and cognitive function and has immunomodulatory, anti-inflammatory, and antioxidant effects⁸. Homocysteine is thought to be a pro-atherogenic molecule that has toxic effects on endothelium, but its associations with diagnosis and prognostic evaluation of SCH have not been systematically analyzed and summarized⁹. Consistent with vitamin B₁₂, folate is a vitamin B used to modulate cell division. Folate deficiency is closely implicated in megaloblastic anemia, cardiovascular disease, osteoporosis, bone dysplasia, depression, and SCH, and folate insufficiency during pregnancy may cause fetal neural tube developmental defects. SCH involves neurodegenerative processes, although the impact extent of vitamin deficiency on these processes remains unclear¹⁰, and the potential deterioration of such processes resulting from folate and vitamin B₁₂ deficiencies cannot be ignored. For this reason, efforts should be made to identify patients at risk of specific vitamin deficiencies and then provide prompt and appropriate interventions.

Consequently motivated, the clinical efficacy and safety of folate and vitamin B12 as

adjuvant therapy in SCH were systematically reviewed and meta-analyzed to guide the clinical medication of SCH.

MATERIALS AND METHODS

Retrieval methods

Publication retrieval was performed using databases such as the Cochrane Library, PubMed, Web of Science, and EMBASE, as well as related websites for registration of clinical trial institutions with “schizophrenia”, “cognitive impairment”, “SCH”, “folate”, and “vitamin B₁₂” as subject words and trademark names of relevant drugs as free words. In addition, relevant studies published in English were retrieved to avoid bias due to language restrictions (Fig. 1).

Inclusion criteria

The inclusion criteria of studies were as follows: i) studies using randomized controlled trials (RCTs), ii) those with research subjects meeting the diagnostic criteria for SCH following the Minnesota Multiphasic Personality Inventory or schizophrenia scale and also the ICD-11 diagnosis of schizophrenia¹¹, iii) those researching comparisons of efficacy and safety between folate and vitamin B₁₂ as adjuvant therapies for SCH, iv) those mainly evaluating indexes including anxiety relief rate, incidence rate of mania, total efficacy and incidence rate of adverse reactions, v) those whose research subjects had no history of drug abuse, and vi) those including research subjects who underwent 6-12 weeks of treatment and were aged ≥ 8 years old and lack of folate or vitamin B₁₂.

Exclusion criteria

The exclusion criteria involved: i) studies adopting non-RCTs, ii) repeated studies, iii) studies with incomplete data, or iv) studies published for the second time.

Quality evaluation of studies

Evaluation was performed as required: i) whether patients were ranked randomly




Fig. 1. Flow chart of literature retrieval.

(“yes” =2, “unclear” =1, “no” =0), ii) random hiding (“yes” =2, “unclear” =1, “no” =0), iii) blind trial (“yes” =2, “clear” =1, “no” =0), and iv) withdrawal or not withdrawal (“yes” =1, “no” =0). Data involving author information and country, Jadad score, type, patient’s age and gender, the dose of study drugs, number of cycles, effective treatment, total efficacy score after treatment, and adverse reactions were extracted. Then two commentators were responsible for comparing these data, where inconsistencies were discussed, and missing information was supplemented as far as possible.

Bias analysis of studies

Two investigators independently conducted data extraction and cross-checking to ensure the data’s accuracy. Quality evaluation was conducted for RCTs with the Cochrane Handbook 5.0.2 as a reference. As for the included studies, the presence or absence of publication bias was evaluated using a funnel chart (performed through the Egger’s test), which illustrated that all studies were within the triangle area, without obvious publication bias (Figs. 2 and 3).

Statistical analysis

The Review Manager 5.2 software [Cochrane Information Management System (IMS)] provided by Cochrane Collaboration was utilized for statistical analysis using the hazard ratio of binary variables. The meta-analysis analyzed the efficacy and incidence rate of adverse reactions using relative risk (RR) and 95% confidence interval (CI). Besides, the chi-square test (the significance level was set at $p < 0.05$) and t -test expressed by Z and P values for the hypothesis test were applied, and $p < 0.05$ was considered statistically significant. The hypothesis test results were displayed in the forest plot, and the χ^2 test was employed to analyze heterogeneity, divided into low, medium, and high heterogeneity and represented by $I^2 = 25\%$, 50% , and 75% , respectively. The inverted funnel chart was used and displayed no obvious publication bias.

RESULTS

Basic information of included patients

A total of 123 studies were obtained by the preliminary retrieval based on databases such as PubMed, Cochrane Library, Web of




Fig. 2. Quality evaluation chart of literatures.




Fig. 3. Funnel chart for analysis of literature publication bias.

Science, and EMBASE. Furthermore, relevant references were also retrieved to avoid omission. Fourteen studies adopting RCTs were included (Table 1) ¹²⁻²⁵.

Anxiety relief rate in SCH patients undergoing adjuvant therapy with folate and vitamin B₁₂

A heterogeneity test found that a low level of heterogeneity existed in 14 studies adopting RCTs for detecting anxiety relief rates in SCH patients undergoing adjuvant therapy with folate and vitamin B₁₂, so fixed models were utilized for meta-analysis. The experimental group was given folate in combination with vitamin B₁₂, and the control group was only given folate. The two groups had significantly different remission rates of anxiety [odds ratio (OR)=1.28, 95% CI (1.02, 1.61), $p=0.03$, $I^2=0\%$, $Z=2.13$] (Fig. 4).

Incidence rate of mania in SCH patients undergoing adjuvant therapy with folate and vitamin B₁₂

A heterogeneity test was conducted and revealed that 14 studies adopting RCTs for investigating the incidence rate of mania in SCH patients undergoing adjuvant therapy with folate and vitamin B₁₂ exhibited a low level of heterogeneity, which could be subject to meta-analysis with fixed models. The results manifested that there was no significant difference in the incidence rate of mania in SCH patients undergoing adjuvant therapy with folate and vitamin B₁₂ between the experimental group and the control group [OR=1.13, 95% CI (0.78, 1.65), $p=0.65$, $I^2=36\%$, $Z=0.65$] (Fig. 5).

Total efficacy of folate and vitamin B₁₂ in the adjuvant treatment of SCH

A heterogeneity test was performed and manifested that 14 studies adopting RCTs for examining the total efficacy of adjuvant therapy with folate and vitamin B₁₂ for SCH showed a low level of heterogeneity, which were subject to meta-analysis with fixed

models. The results demonstrated that the total efficacy of adjuvant therapy with folate and vitamin B₁₂ for SCH showed no significant difference between the experimental group and the control group [OR=1.06, 95% CI (0.72, 1.56), $p=0.77$, $I^2=0\%$, $Z=0.30$] (Fig. 6).

Incidence rate of adverse reactions of folate and vitamin B₁₂ in the adjuvant treatment of SCH

Through a heterogeneity test, it was uncovered that 14 studies adopting RCTs for detecting the incidence rate of adverse reactions of folate and vitamin B₁₂ in the adjuvant treatment of SCH had a low level of heterogeneity, so fixed models were used for meta-analysis. The results confirmed that the incidence rate of adverse reactions of adjuvant therapy with folate and vitamin B₁₂ for SCH exhibited no significant difference between the experimental group and the control group [OR=1.15, 95% CI (0.88,1.49), $p=0.31$, $I^2=0\%$, $Z=1.03$] (Fig. 7).

DISCUSSION

Folate and vitamin B₁₂ have immunomodulatory, anti-inflammatory, and antioxidant properties. It has been reported that the incidence of vitamin D deficiency is raised in patients newly diagnosed with SCH²⁶. Another study demonstrated that vitamin B₁₂ is not only associated with malnutrition but also correlated with the occurrence of disease and increased incidence rate of autoimmune thyroid diseases. Consequently, the loss of the neuroprotective effect of vitamin B₁₂ may be implicated in the pathogenesis of SCH²⁷. Like SCH, substance use disorder (SUD) is a chronic disease usually related to malnutrition. In a study about associations of folate and vitamin B₁₂ levels with the severity of symptoms in patients with SCH, those with low levels of vitamin B₁₂ may be at particular risk of poor prognosis. A previous study also revealed lower folate levels in SCH patients than in healthy controls²⁸. Howev-

Table 1
Basic information of patients in 14 literatures adopting RCTs.

Study item	Age	Gender (Male)	Observation index of outcome	Experimental group (N)	Control group (N)	NOS score	Study type
Yazici et al. 2019	41.44±12.28	57.14%	Anxiety relief rate, incidence rate of mania, etc.	119/189	109/189	8	RCT
Yazici et al. 2019	40.63±13.50	100%	Anxiety relief rate, incidence rate of mania, etc.	24/30	23/28	7	RCT
Altun et al. 2018	9.33±1.80	76.67%	Anxiety relief rate, incidence rate of mania, etc.	23/30	25/30	8	RCT
Hope et al. 2020	30.0±9.0	55.78%	Anxiety relief rate, incidence rate of mania, etc.	420/483	401/483	8	RCT
Allott et al. 2019	20.2±3.0	65.40%	Anxiety relief rate, incidence rate of mania, etc.	88/120	76/120	8	RCT
Topal et al. 2022	8.5±3.1	73.90%	Anxiety relief rate, incidence rate of mania, etc.	178/203	180/203	7	RCT
Ramaekers et al. 2014	19.5±2.56	78.20%	Anxiety relief rate, incidence rate of mania, etc.	12/18	13/18	9	RCT
Chen et al. 2021	44.3±10.7	49.60%	Anxiety relief rate, incidence rate of mania, etc.	125/232	117/232	9	RCT
Misiak et al. 2014	26.0±5.3	58.97%	Anxiety relief rate, incidence rate of mania, etc.	27/39	31/39	7	RCT
Kale et al. 2010	33.57±8.35	56.32%	Anxiety relief rate, incidence rate of mania, etc.	23/31	26/48	8	RCT
Roffman et al. 2013	45.3±1.1	71.0%	Anxiety relief rate, incidence rate of mania, etc.	31/56	28/56	8	RCT
Saedisoomeolia et al. 2011	37.25±16.0	66.44%	Anxiety relief rate, incidence rate of mania, etc.	44/60	41/60	8	RCT
Misiak et al. 2016	28.51±8.6	68.44%	Anxiety relief rate, incidence rate of mania, etc.	117/135	121/146	9	RCT
Misiak et al. 2015	25.12±4.48	43.22%	Anxiety relief rate, incidence rate of mania, etc.	34/83	36/83	7	RCT




Fig. 4. Meta-analysis of anxiety relief rate in SCH patients undergoing adjuvant therapy between the two groups.




Fig. 5. Meta-analysis of incidence rate of mania in SCH patients undergoing adjuvant therapy between the two groups.





Fig. 6. Meta-analysis of total efficacy of adjuvant therapy for SCH between the two groups.



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Fig. 7. Meta-analysis of incidence rate of adverse reactions in SCH patients undergoing adjuvant therapy between the two groups.

er, these findings have not been reported in other studies. Consistent with previous studies, folate, and vitamin B₁₂ are relatively deficient in older adults, verifying associations with gender and age^{29,31}.

It has long been considered that abnormal one-carbon metabolism is one of the mechanisms for the neuropathology and psychopathology of SCH³². The changes in levels of one-carbon metabolic components (folate and vitamin B₁₂), homocysteine, and docosahexaenoic acid (DHA) are primarily found in patients receiving drug administration. For instance, daily administration of 2 mg folate plus 1 mg vitamin B₁₂ for 12 weeks can significantly reduce the serum homocysteine level ($p < 0.0001$)³³. In a relevant study, the impact of change levels of one-carbon metabolic components (folate and vitamin B₁₂) on the severity of SCH was reported, and the subsequent alterations of homocysteine and DHA in phospholipids were also notably correlated with the pathogenesis of SCH³⁴. In a study conducted by Satoskar *et al.*³⁵, the associations of folate and vitamin B₁₂ deficiencies with the pathogenesis and prognosis of SCH patients were investigated, and the mechanism of one-carbon metabolism was also further explored. In the study, the clinical efficacy and safety

of agents were analyzed between first-episode psychosis (FEP) patients (n=31) and healthy controls (HC, n=48), and folate and vitamin B₁₂ were matched with confounding factors such as race, diet, and lifestyle, to reduce variability. Compared with HC, the DHA level in patients with FEP noticeably declined. The unique cohort used in the study provided an extensive mechanism for changing one-carbon metabolism (disturbed folate-vitamin B₁₂-DHA balance). Besides, the increased level of homocysteine contributes to the mechanism research on the neuropathology of SCH, and the data mentioned above may be of great significance for the psychopathology of SCH³⁶⁻³⁹.

The limitations of this meta-analysis include: i) Potential publication bias existed because of too few studies and small sample size. ii) There were few studies included and no subgroup analysis for comparison of efficacy. iii) Only therapeutic effects at the end of treatment were evaluated, but long-term effects were not assessed. iii) We only included adult SCH patients over the age of 18, whose results would be inapplicable to adolescents.

Vitamin B₁₂ and folate levels are notably lower in patients with SCH^{40,41}. Herein, further analysis on the clinical efficacy and

safety of adjuvant therapy with folate and vitamin B₁₂ for SCH revealed that vitamin B₁₂ differed significantly from folate in terms of anxiety relief rate ($p < 0.05$). However, there were no significant differences in the incidence rate of mania, total efficacy, and incidence rate of adverse reactions ($p > 0.05$). Although vitamin deficiency commonly occurs in patients with SCH, vitamin B₁₂ has notably fewer side effects than folate drugs, which is consistent with the findings of Roffman *et al.*⁴². Hence, this meta-analysis is of great guiding significance for the adjuvant clinical medication of SCH.

ACKNOWLEDGMENTS

This study was not financially supported.

Conflict of interest

The authors declare no conflict of interest.

Authors ORCID

- Kai Niu (KN):
0000-0003-0314-9735
- Ximin Zhao (XZ):
0000-0001-5924-0058
- Ying Wei (YW):
0000-0001-7642-3614
- Yuefeng Wang (YFW):
0000-0001-9064-3525

Authors' contribution

Study design: KN, XZ; Data collection: YW, YFW; Data analysis: YW, YFW; Writing: KN, XZ. KN and XZ contributed equally to this study.

REFERENCES

1. Ma F, Zhou X, Li Q, Zhao J, Song A, An P, Du Y, Xu W, Huang G. Effects of folic acid and vitamin B₁₂, alone and in combination on cognitive function and inflammatory factors in the elderly with mild cognitive impairment: a single-blind experimental design. *Curr Alzheimer Res* 2019; 16(7): 622-632. <https://doi.org/10.2174/1567205016666190725144629>.
2. van de Leemput J, Hess JL, Glatt SJ, Tsuang MT. Genetics of schizophrenia: historical insights and prevailing evidence. *Adv Genet* 2016; 96: 99-141. <https://doi.org/10.1016/bs.adgen.2016.08.001>.
3. Satapathy S, Bandyopadhyay D, Patro BK, Khan S, Naik S. Folic acid and vitamin B₁₂ supplementation in subjects with type 2 diabetes mellitus: A multi-arm randomized controlled clinical trial. *Complement Ther Med* 2020; 53: 102526. <https://doi.org/10.1016/j.ctim.2020.102526>.
4. Richetto J, Meyer U. Epigenetic modifications in schizophrenia and related disorders: molecular scars of environmental exposures and source of phenotypic variability. *Biol Psychiatry* 2021; 89(3): 215-226. <https://doi.org/10.1016/j.biopsych.2020.03.008>.
5. Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B₁₂ for depression. *Int Psychogeriatr* 2015; 27(5): 727-737. <https://doi.org/10.1017/S1041610215000046>.
6. Bortolon C, Macgregor A, Capdevielle D, Raffard S. Apathy in schizophrenia: A review of neuropsychological and neuroanatomical studies. *Neuropsychologia* 2018; 118(Pt B): 22-33. <https://doi.org/10.1016/j.neuropsychologia.2017.09.033>.
7. Guéant JL, Guéant-Rodríguez RM, Alpers DH. Vitamin B₁₂ absorption and malabsorption. *Vitam Horm* 2022; 119: 241-274. <https://doi.org/10.1016/bs.vh.2022.01.016>.
8. Izawa J, Asai T, Imamizu H. Computational motor control as a window to understanding schizophrenia. *Neurosci Res* 2016; 104: 44-51. <https://doi.org/10.1016/j.neures.2015.11.004>.
9. Shen L, Ji HF. Associations between homocysteine, folic acid, vitamin B₁₂ and Alzheimer's Disease: insights from meta-

- analyses. *J Alzheimers Dis* 2015; 46(3): 777-790. <https://doi.org/10.3233/JAD-150140>.
10. **Hosák L, Silhan P, Hosáková J.** Genome-wide association studies in schizophrenia, and potential etiological and functional implications of their results. *Acta Medica* 2012; 55(1): 3-11. <https://doi.org/10.14712/18059694.2015.67>.
 11. **Hsu YC, Ye Z, Dai L, Jing Y, Tsui KL, Yip PS, Li W, Zhang Q.** Understanding MMPI-2 response structure between schizophrenia and healthy individuals. *Front Psychiatry* 2022; 13: 918999. <https://doi.org/10.3389/fpsy.2022.918999>.
 12. **Yazici AB, Akcay Ciner O, Yazici E, Cilli AS, Doğan B, Erol A.** Comparison of vitamin B₁₂, vitamin D and folic acid blood levels in patients with schizophrenia, drug addiction and controls. *J Clin Neurosci* 2019; 65: 11-16. <https://doi.org/10.1016/j.jocn.2019.04.031>.
 13. **Yazici E, Mutu Pek T, Guzel D, Yazici AB, Akcay Ciner O, Erol A.** Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients. *Nord J Psychiatry* 2019; 73(3): 178-184. <https://doi.org/10.1080/08039488.2019.1582697>.
 14. **Altun H, Şahin N, Belge Kurutaş E, Güngör O.** Homocysteine, pyridoxine, folate and vitamin B₁₂ levels in children with attention deficit hyperactivity disorder. *Psychiatr Danub* 2018; 30(3): 310-316. <https://doi.org/10.24869/psyd.2018.310>.
 15. **Hope S, Naerland T, Høiland AL, Torske T, Malt E, Abrahamsen T, Nerhus M, Wedervang-Resell K, Lonning V, Johannessen J, Steen NE, Agartz I, Stenberg N, Hundhausen T, Mørkrid L, Andreassen OA.** Higher vitamin B₁₂ levels in neurodevelopmental disorders than in healthy controls and schizophrenia: A comparison among participants between 2 and 53 years. *FASEB J* 2020; 34(6): 8114-8124. <https://doi.org/10.1096/fj.201900855RRR>.
 16. **Allott K, McGorry PD, Yuen HP, Firth J, Proffitt TM, Berger G, Maruff P, O'Regan MK, Papas A, Stephens TCB, O'Donnell CP.** The vitamins in psychosis study: a randomized, double-blind, placebo-controlled trial of the effects of vitamins B₁₂, B₆, and folic acid on symptoms and neurocognition in first-episode psychosis. *Biol Psychiatry* 2019; 86(1): 35-44. <https://doi.org/10.1016/j.biopsych.2018.12.018>.
 17. **Topal Z, Tufan AE, Karadağ M, Gokcen C, Akkaya C, Sarp AS, Bahsi I, Kilinc M.** Evaluation of peripheral inflammatory markers, serum B₁₂, folate, ferritin levels and clinical correlations in children with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). *Nord J Psychiatry* 2022; 76(2): 150-157. <https://doi.org/10.1080/08039488.2021.1946712>.
 18. **Ramaekers VT, Thöny B, Sequeira JM, Ansseau M, Philippe P, Boemer F, Bours V, Quadros EV.** Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies. *Mol Genet Metab* 2014; 113(4): 307-314. <https://doi.org/10.1016/j.ymgme.2014.10.002>.
 19. **Chen CH, Chen PY, Chen CY, Chiu CC, Lu ML, Huang MC, Lin YK, Chen YH.** Associations of genetic variants of methylenetetrahydrofolate reductase and serum folate levels with metabolic parameters in patients with schizophrenia. *Int J Environ Res Public Health* 2021; 18(21): 11333. <https://doi.org/10.3390/ijerph182111333>.
 20. **Misiak B, Frydecka D, Kiejna A.** Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. *Eur J Clin Pharmacol* 2014; 70(12): 1433-1441. <https://doi.org/10.1007/s00228-014-1762-2>.
 21. **Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S.** Reduced folic acid, vitamin B₁₂ and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. *Psychiatry Res* 2010; 175(1-2): 47-53. <https://doi.org/10.1016/j.psychres.2009.01.013>.
 22. **Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Sil-**

- verstein NJ, Smoller JW, Hill M, Goff DC. Randomized multicenter investigation of folate plus vitamin B₁₂ supplementation in schizophrenia. *JAMA Psychiatry* 2013; 70(5): 481-489. <https://doi.org/10.1001/jamapsychiatry.2013.900>.
23. Saedisomeolia A, Djalali M, Moghadam AM, Ramezankhani O, Najmi L. Folate and vitamin B₁₂ status in schizophrenic patients. *J Res Med Sci* 2011; 16 Suppl 1: S437-S441. PMID: 22247731.
 24. Misiak B, Łaczmanski Ł, Słoka NK, Szmidła E, Piotrowski P, Loska O, Ślęzak R, Kiejna A, Frydecka D. Metabolic dysregulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism. *Psychiatry Res* 2016; 238: 60-67. <https://doi.org/10.1016/j.psychres.2016.01.077>.
 25. Misiak B, Kiejna A, Frydecka D. The history of childhood trauma is associated with lipid disturbances and blood pressure in adult first-episode schizophrenia patients. *Gen Hosp Psychiatry* 2015; 37(4): 365-367. <https://doi.org/10.1016/j.genhosppsy.2015.03.017>.
 26. Gadgil M, Joshi K, Pandit A, Otiv S, Joshi R, Brenna JT, Patwardhan B. Imbalance of folic acid and vitamin B₁₂ is associated with birth outcome: An Indian pregnant women study. *Eur J Clin Nutr* 2014; 68(6): 726-729. <https://doi.org/10.1038/ejen.2013.289>.
 27. Möller HJ. Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives? *Eur Arch Psychiatry Clin Neurosci* 2018; 268(6): 525-527. <https://doi.org/10.1007/s00406-018-0926-y>.
 28. Lawrie SM, Hall J, McIntosh AM, Cunningham-Owens DG, Johnstone EC. Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. *Br J Pharmacol* 2008; 153 Suppl 1: S120-S124. <https://doi.org/10.1038/sj.bjp.0707655>.
 29. Rothenberg SP. Application of competitive ligand binding for the radioassay of vitamin B₁₂ and folic acid. *Metabolism* 1973; 22(8): 1075-1082. [https://doi.org/10.1016/0026-0495\(73\)90226-6](https://doi.org/10.1016/0026-0495(73)90226-6).
 30. Roberts MT, Shokrane F, Sun Y, Groom M, Adams CE. Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies. *Evid Based Ment Health* 2021; 24(2): 62-69. <https://doi.org/10.1136/ebmental-2020-300151>.
 31. Lin CH, Yang S, Huang YJ, Lane HY. Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia. *Sci Rep* 2019; 9(1): 18840. <https://doi.org/10.1038/s41598-019-55414-1>.
 32. Dang S, Yan H, Zeng L, Wang Q, Li Q, Xiao S, Fan X. The status of vitamin B₁₂ and folate among Chinese women: a population-based cross-sectional study in northwest China. *PLoS One* 2014; 9(11): e112586. <https://doi.org/10.1371/journal.pone.0112586>.
 33. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B₁₂ for cognition and dementia. *Cochrane Database Syst Rev* 2003; (4): CD004514. <https://doi.org/10.1002/14651858.CD004514>
 34. Pomarol-Clotet E, Salvador R, Murray G, Tandon S, McKenna PJ. Are there valid subtypes of schizophrenia? A grade of membership analysis. *Psychopathology* 2010; 43(1): 53-62. <https://doi.org/10.1159/000260044>.
 35. Satoskar RS, Kulkarni BS, Mehta BM. Serum vitamin B₁₂ and folic acid (P.G.A.) levels in hypoproteinaemia and marasmus in Indian children. *Arch Dis Child* 1962; 37(191): 9-16. <https://doi.org/10.1136/adc.37.191.9>.
 36. McIntosh AM, Gow A, Luciano M, Davies G, Liewald DC, Harris SE, Corley J, Hall J, Starr JM, Porteous DJ, Tenesa A, Visscher PM, Deary IJ. Polygenic risk for schizophrenia is associated with cognitive change between childhood and old age. *Biol Psychiatry* 2013; 73(10): 938-943. <https://doi.org/10.1016/j.biopsych.2013.01.011>.

37. **Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M.** Homocysteine, folate and vitamin B₁₂ in neuropsychiatric diseases: review and treatment recommendations. *Expert Rev Neurother* 2009; 9(9): 1393-1412. <https://doi.org/10.1586/ern.09.75>.
38. **Cocchi E, Drago A, Serretti A.** Hippocampal pruning as a new theory of schizophrenia Etiopathogenesis. *Mol Neurobiol* 2016; 53(3): 2065-2081. <https://doi.org/10.1007/s12035-015-9174-6>.
39. **Girdwood RH.** Abnormalities of vitamin B₁₂ and folic acid metabolism--their influence on the nervous system. *Proc Nutr Soc* 1968; 27(1): 101-107. <https://doi.org/10.1079/pns19680021>.
40. **Yang QX, Wang YX, Li FC, Zhang S, Luo YC, Li Y, Tang J, Li B, Chen YZ, Xue WW, Zhu F.** Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility. *CNS Neurosci Ther* 2019; 25(9): 1054-1063. <https://doi.org/10.1111/cns.13196>.
41. **Williams JN.** Some metabolic interrelationships of folic acid, vitamin B₁₂, and ascorbic acid. *Am J Clin Nutr* 1955; 3(1): 20-29. <https://doi.org/10.1093/ajcn/3.1.20>.
42. **Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC.** Randomized multicenter investigation of folate plus vitamin B₁₂ supplementation in schizophrenia. *JAMA Psychiatry* 2013; 70(5): 481-489. <https://doi.org/10.1001/jamapsychiatry.2013.900>.